Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to evaluate the effectiveness of NeuroResource Facilitation, a novel/innovative intervention, in reducing recidivism in offenders with brain injury (BI).


Clinical Trial Description

The prevalence of brain injury (BI) is significantly greater in justice-involved populations, and a substantial proportion of prisoners have likely experienced a BI during their lifetime. A history of BI has a statistically significant association with increased use of correctional, medical and psychological services including crisis intervention; an increased frequency of institutional misconducts; and higher recidivism rates. Brain injury in justice-involved populations is frequently undiagnosed, and therefore untreated, which contributes to the cycle of recidivism. Identifying BI opens up new resources to ex- offenders that can more effectively help them to become productive in their lives in the community. In partnership with the Icahn School of Medicine at Mount Sinai, the Brain Injury Association of Pennsylvania, and the Pennsylvania Department of Corrections (PADOC), this project will implement a randomized clinical trial to determine if a case management intervention called Neurorehabilitation Facilitation (NRF) is effective in reducing recidivism by ten percent in offenders with acquired BI. Offenders in two Pennsylvania prisons (State Correctional Institution (SCI) sites in PA, SCI Phoenix, SCI Chester, SCI Frackville, and SCI Mahanoy) will be screened for BI and cognitive impairment, and those who screen positive will be randomized to receive the intervention or to receive standard of care (SoC). Two thirds of those randomized will receive the intervention and the remaining one third will serve as controls. All participants will be followed for up to three years following their release to examine the immediate and long-term reduction in recidivism. The primary hypothesis is that NRF, as compared to SoC, will result in a 10% reduction in average 1-year recidivism, estimated by the 2013 Department of Corrections (DOC) report as 35-38%. Understanding that additional factors will contribute to the effect of NRF, the required sample was based on the primary analysis, a logistic regression of the binary response variable recidivism, adjusted for additional independent variables (described below) in the model with estimated R-squared=0.10. An effect size of 10% reduction corresponds to an odds ratio in this model of 0.643. With two thirds (67%) of cases randomized to NRF, and one third (33%) randomized to SoC, a total sample of N=688 provides 80% power at alpha set at 0.05. Anticipating that there will be a loss of approximately 10% of randomized cases to attrition, N=764 cases will be randomized, with n=509 cases randomized to NRF and 255 randomized to SoC. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05708092
Study type Interventional
Source Icahn School of Medicine at Mount Sinai
Contact Annell Ovalles, MPH
Phone 212-241-4706
Email annell.ovalles@mountsinai.org
Status Recruiting
Phase N/A
Start date March 22, 2022
Completion date December 2025

See also
  Status Clinical Trial Phase
Completed NCT02710123 - Sub-Threshold Exercise Treatment for Adolescents With Sports Related Concussion N/A
Recruiting NCT02777060 - Exploring the Effectiveness of Sensor-based Balance Training on Patient Outcome Measures N/A
Completed NCT02262286 - MIND (Management of Traumatic Brain Injury Diagnosis) N/A
Completed NCT01461902 - Vasospasm in Pediatric Traumatic Brain Injury N/A
Recruiting NCT01198964 - Optimization of Human Cortical Stimulation
Active, not recruiting NCT01207050 - Effect of Rozerem on Sleep Among People With Traumatic Brain Injury Phase 4
Completed NCT00875329 - Traumatic Brain Injury (TBI) Screening Instruments N/A
Completed NCT01201863 - Neuroendocrine Dysfunction in Traumatic Brain Injury: Effects of Testosterone Therapy Phase 4
Completed NCT01035606 - Training in Goal-directed Attention Regulation for Individuals With Brain Injury N/A
Completed NCT01059890 - Cerebral Antibiotics Distribution After Acute Brain Injury Phase 1
Completed NCT00571623 - Automated Chest Physiotherapy to Improve Outcomes in Neuro N/A
Completed NCT00596765 - Neuropsychological Cognitive Behavioral Therapy for Patients With Acquired Brain Injury N/A
Completed NCT00336466 - The Erythropoietin NeuroProtective Effect: Assessment in CABG Surgery (TENPEAKS) Phase 2
Recruiting NCT05105763 - Biofeedback Gait Retraining for Stiff Knee Gait Correction N/A
Recruiting NCT02495558 - Cough Assessment in Patients With Severe Acquired Brain Injury N/A
Completed NCT02100592 - Early Verticalization in neuroICU With ERIGO: a Safety and Feasibility Study Phase 1/Phase 2
Completed NCT00797680 - Duration of Hypothermia for Neuroprotection After Pediatric Cardiac Arrest Phase 2
Completed NCT00018499 - Genotype Influence on Recovery After Traumatic Brain Injury N/A
Recruiting NCT02567201 - Electrophysiological Evaluation of Voluntary Attention N/A
Withdrawn NCT05581927 - Whole-Body Hypothermia for Neonates With Hypoxic-Ischemic Encephalopathy(HIE) N/A